{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.0","value":"8160"},{"groupId":"OG001","spread":"59.1","value":"16900"},{"groupId":"OG002","spread":"20.8","value":"21000"},{"groupId":"OG003","spread":"39.2","value":"25300"},{"groupId":"OG004","spread":"0.0","value":"2100"},{"groupId":"OG005","spread":"0.0","value":"30500"},{"groupId":"OG006","spread":"0.0","value":"16500"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"}],"units":"Participants"}],"title":"AUC0-24h"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.3","value":"8210"},{"groupId":"OG001","spread":"50.0","value":"18000"},{"groupId":"OG002","spread":"51.2","value":"17200"},{"groupId":"OG003","spread":"39.0","value":"25600"},{"groupId":"OG004","spread":"118.4","value":"5840"},{"groupId":"OG005","spread":"113.2","value":"125000"},{"groupId":"OG006","spread":"1.8","value":"16700"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"2"}],"units":"Participants"}],"title":"AUClast"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"2"}],"units":"Participants"}],"description":"Characterize single and multiple-dose PK of LDK378 in pediatric patients. AUC: Area under the plasma (serum, or blood) concentration versus time curve AUClast: Area under the concentration-time curve from time zero to the last measureable concentration time; AUC0-24h: Area under the plasma concentration-time curve t=0-24 h","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants in the fasted group who took 300 mg of ceritinib","id":"OG000","title":"Fasted: Ceritinib 300 mg/m2"},{"description":"Participants in the fasted group who took 450 mg of ceritinib","id":"OG001","title":"Fasted: Ceritinib 450 mg/m2"},{"description":"Participants in the fasted group who took 510 mg of ceritinib","id":"OG002","title":"Fasted: Ceritinib 510 mg/m2"},{"description":"Participants in the fasted group who took 560 mg of ceritinib","id":"OG003","title":"Fasted: Ceritinib 560 mg/m2"},{"description":"Participants in the fed group who took 320 mg of ceritinib","id":"OG004","title":"Fed: Ceritinib 320 mg/m2"},{"description":"Participants in the fed group who took 400 mg of ceritinib","id":"OG005","title":"Fed: Ceritinib 400 mg/m2"},{"description":"Participants in the fed group who took 500 mg of ceritinib","id":"OG006","title":"Fed: Ceritinib 500 mg/m2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set (PAS) consisted of all patients who received at least one dose of ceritinib and had at least one evaluable PK sample.","reportingStatus":"POSTED","timeFrame":"0hr pre-dose, 2, 4, 6 & 24hrs post-dose","title":"Pharmacokinetics (PK) Parameters: AUC0 - 24h & AUClast in Cycle 2 Day 1 - Dose Escalation Phase (Single Dose)","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}